Search PubMed⌕ Search

Biomedical subjects

S Onodera

Publications and source records attributed to S Onodera.

At least 289 records · Page 16Linked to original sources
PubMed1976

An IgG M-component reacting with both anti-kappa and anti-gamma light chains in multiple myeloma.

A patient with multiple myeloma who has an IgG-IM-component in serum reacting with both kappa and lambda light chains in immunoelectrophoresis is presented. The possibility of "hybrid molecule (H2LkappaLlambda)" is strongly suspected. The absorption studies of the patient's serum employing anti-kappa and anti-lambda light chains, however, support the view that this apparently single M-component consists of two M-components, IgG 1-kappa and IgG 1-lambda. The reason why these two M-components possessed the identical electrophoretic mobility is unclear. The possibility is high that these two M-components are produced in the same cell.

Aged↗
PubMed1975

Renal impairment in patients with paroxysmal nocturnal hemoglobinuria.

Three patients with paroxysmal nocturnal hemoglobinuria accompanied by chronic renal lesions were studied. All the cases had histories of severe hemolytic anemia and repeated hemoglobinuria. The biopsy specimen of the kidney of two patients (Case 1 and Case 2) showed interstitial nephritis. Renal glucosuria, tubular proteinuria, increased urate clearance (Case 2) and reduced tubular reabsorption of phosphate (Case 3) were revealed in Case 2 and Case 3, suggesting renal tubular impairment. From the nephrological point of view, hemodynamic alteration resulting from intravascular hemolysis and severe persistent chronic anemia may primarily be responsible for the renal impairment.

Adult↗
PubMed1975

Treatment of multiple myeloma and macroglobulinemai Waldenström: A long-term follow-up study.

Fifteen cases of multiple myeloma and 6 cases of macroglobulin emia Waldenstrom were followed up from 1957 to 1974. As for administration of drugs a low continuous dose regimen was mainly employed instead of a high intermittent dose regimen. 50% survival time from the onset of the disease was 18 months for multiple myeloma and 25 months for macroglobulinemia Waldenstrom. 3 cases of multiple myeloma are still living 44 months after the onset of symptoms. Cyclophosphamide and melphalan seem to have contributed much to the prolonged survival of these patients as well as improved supportive care.

Adult↗